Lilly's Retatrutide Shows Up to 28.3% Weight Loss in Phase 3 Trials, Reinforcing GLP-1 Dominance
LLY sits 71% above its 52-week low of $623.78.
Summary
Eli Lilly's investigational drug Retatrutide achieved significant weight loss of up to 28.3% (70.3 lbs) over 80 weeks in Phase 3 trials, with approximately 45% of participants achieving at least 30% weight loss. This strong clinical data for another key pipeline asset further solidifies Lilly's leading position in the rapidly growing GLP-1 and weight loss treatment market, following recent FDA approval for Foundayo. The results indicate a highly competitive profile for Retatrutide, reinforcing the company's long-term growth prospects.
At the time of this announcement, LLY was trading at $1,064.59 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.